KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aproximadaProbabilidad implícita actualSí 98%
Calidad del mercado
44 / 100
Baja calidadVolumen 24h
0 €
Liquidez
922,9 €
Baja liquidezCompra / Venta
80.0% / 86.0%
Spread
6.0 pt
Spread amplioDatos de mercado
Actualizado hace 22 minutos
17 jun 26, 21:001 ene 27, 4:59
Tendencias
Solo fondos simulados, sin dinero realNo es asesoramiento financiero
Resultado elegido
Yes98%
Tendencia de volumen
$8123 jul10d de datos26 jul
Mercados Relacionados
Hantavirus pandemic in 2026?
91 mil €Sí: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
12,9 mil €26-27M: 93%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
4,9 mil €Sí: 3%POLYMARKET
POLYMARKET
Measles cases in 2026?
2,9 mil €Above 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
2,1 mil €Sí: 5%KALSHI
KALSHI
Cyclosporiasis cases reported in the US in 2026?
1,2 mil €Above 20k: 34%KALSHI
KALSHIActivos en estos temas
Reglas
If the FDA's decision on Brepocitinib by Priovant Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Brepocitinib is an experimental oral pill developed by Priovant Therapeutics that is designed to calm an overactive immune system in people with certain inflammatory diseases.
- Think of it like a circuit breaker for runaway immune signals: it blocks specific molecular switches inside immune cells that, when left unchecked, drive damaging inflammation throughout the body.
- In the VALOR trial , it is being tested as a treatment for dermatomyositis, a rare disease in which the immune system attacks the body's own muscles and skin.